Reference
1. 보건복지부 홈페이지
Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID =0403&page=1&CONT_SEQ=369207
2. 식품의약품안전처 홈페이지
Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq=45965
3. 보건복지부 홈페이지
Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID =0403&CONT_SEQ=368818
4. 식품의약품안전처 홈페이지
Available from: https://www.mfds.go.kr/brd/m_1059/view.do?seq=14873
5. 박희윤 기자 “KBIOHealth, 범부처재생의료기술개발사업단 맞손 서울경제” (’21.12.16)
Available from: https://www.sedaily.com/NewsVIew/22VBDBP6Y2
6. 범부처재생의료기술개발사업단 홈페이지
Available from: http://www.kfrm.org/doc/html/information/newsView.asp?BOARD_IDX=191
7. 산업통상자원부 홈페이지
Available from: http://www.motie.go.kr/motie/ne/presse/press2/bbs/bbsView.do?bbs_cd_n=81&bbs_seq_n=164970
8. 김진우 기자 “한국제약바이오협회, 제6회 바이오 오픈 플라자 개최” 의약통신(’21.12.14)
Available from: http://www.kmpnews.co.kr/news/articleView.html?idxno=46002
9. 이상철 기자 “서울성모병원, 국내 유일 첨단재생바이오법 전 부문 승인” 후생신보(’21.12.22)
Available from: http://www.whosaeng.com/132775
10. 김진우 기자 “서울대병원, 소아백혈병 CAR-T 치료제, 국내 최초 생산” 의약통신(’21.12.10)
Available from: http://www.kmpnews.co.kr/news/articleView.html?idxno=45945
11. “FDA extends review of &, Legend’s cell theraphy for multiple myeloma” Biopharmadive. Last modified Nov 2. 2021, Accessed Nov 3. 2021,
Available from: https://www.biopharmadive.com/news/johnson-johnson-legend-myeloma- cell-therapy-fda-delay/609274/
12. “Regenerative Medicine 101 Webinar: Information for Patients, Caregivers & Advocates” US FDA, Last modified Nov 16. 2021, Accessed Nov 17. 2021,
Available from: https://www.fda.gov/news-events/regenerative-medicine-101-webinar- information-patients-caregivers-advocates-11162021-11162021
13. “Regenerative Medicine 101: Information for Patients, Caregivers & Advocates” US FDA, Last modified Dec 8. 2021, Accessed Dec 10. 2021,
Available from: https://fda.zoomgov.com/rec/play/fVlSwsgD7Pi5ZQLXrg7uQcN7x1vlmR3Ris0
nYR0H7bMet_abeUD7exXGko4JLSouVpu6mEYUiCgiiuzA.k5BRYx6acXFEu6TT?startTime=1637078375000
14. “Regenerative Medicine 101: Information for Patients, Caregivers & Advocates” US FDA, Last modified Dec 8. 2021, Accessed Dec 10. 2021,
Available from: https://www.fda.gov/media/154665/download
15. “Beam gets green light to begin first clinical test of base editing” Biopharmadive. Last modified Nov 8. 2021, Accessed Nov 9. 2021,
Available from: https://www.biopharmadive.com/news/beam-clinical-trial-sickle-cell-base- editing-maraganore/609658/
16. “2021 Untitled Letter-NYC Regenerative Medicine, Inc. dba Colts Neck Stem Cells and Regenerative Medicine” US FDA, Last modified Nov 5. 2021, Accessed Nov 8. 2021,
Available from: https://www.fda.gov/media/154054/download
17. “Statistical Review-TECARTUS”, US FDA, Last modified Nov 17. 2021, Accessed Nov 19. 2021,
Available from: https://www.fda.gov/media/154235/download,
18. “Pharmacology/Toxicology Branch TECARTUS”, US FDA, Last modified Nov 17. 2021, Accessed Nov 19. 2021,
Available from: https://www.fda.gov/media/154234/download, https://www.fda.gov/media/ 154234/download
19. “Clinical Review and Evaluation-TECARTUS”, US FDA, Last modified Nov 17. 2021, Accessed Nov 19. 2021,
Available from: https://www.fda.gov/media/154233/download
20. “Bluebird, after delays, gets speedy FDA review for beta thalassemia gene therapy”, Biopharmadive. Last modified Nov 22. 2021, Accessed Nov 24. 2021,
Available from: https://www.biopharmadive.com/news/bluebird-beti-cel-fda-filing-beta- thalassemia/610441/
21. “CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies” CRISPR Therapeutics, Last modified Nov 22. 2021, Accessed Nov 24. 2021, Last modified Nov 22. 2021, Accessed Nov 24. 2021,
Available from: https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr- therapeutics-announces-fda- regenerative-medicine-advanced
22. “Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa”, BioSpace, Last modified Nov 22. 2021, Accessed Nov 24. 2021,
Available from: https://www.biospace.com/article/releases/krystal-biotech-announces-
positive-topline-results-from-gem-3-pivotal-trial-of-vyjuvek-in-patients-with-dystrophic- epidermolysis-bullosa/
23. “FDA In Brief: FDA Takes New Steps Aimed at Advancing Development of Individualized Medicines to Treat Genetic Diseases”,US FDA Last modified Dec 7. 2021, Accessed Dec 10. 2021,
Available from: https://www.fda.gov/news-events/press-announcements/fda-brief-fda-takes -new-steps-aimed-advancing-development-individualized-medicines-treat-genetic
24. “December 8, 2021 Approval Letter ‒ IMLYGIC” US FDA, Last modified Dec 8. 2021, Accessed Dec 10. 2021,
Available from: https://www.fda.gov/media/154750/download
25. “Fresh data show UniQure's hemophilia gene therapy appears to hold up” Biopharmadive. Last modified Dec 9. 2021, Accessed Dec 11. 2021,
Available from: https://www.biopharmadive.com/news/uniqure-gene-therapy-hemophilia- durability/611264/
26. “December 16, 2021 Untitled Letter - Aspen Institute for Regenerative Medicine and Anti-Aging, LLC”, US FDA, Last modified Dec 16. 2021, Accessed Dec 17. 2021,
Available from: https://www.fda.gov/media/154986/download
27. “Duchenne patient dies in Pfizer gene therapy study”, Biopharmadive. Last modified Dec 21. 2021, Accessed Dec 24. 2021,
Available from: https://www.biopharmadive.com/news/pfizer-duchenne-muscular-dystrophy -gene-therapy-death/616421/
28. “Regulatory Submissions in Electronic and Paper Format for CBER-Regulated Products” US FDA, Last modified Dec 22. 2021, Accessed Dec 24. 2021,
Available from: https://www.fda.gov/about-fda/center-biologics-evaluation-and-research- cber/regulatory-submissions-electronic-and-paper-format-cber-regulated-products
29. “KOLON TISSUEGENE RESUMES TG-C PHASE III STUDIES IN THE U.S.”, yahoo!finance, Last modified Dec 29. 2021, Accessed Dec 30. 2021,
Available from: https://finance.yahoo.com/news/kolon-tissuegene-resumes-tg-c-150900038.html
30. 유럽의약품청 EMA 홈페이지
Available from: https://www.ema.europa.eu/en/ich-guideline-s12-nonclinical-biodistribution -considerations-gene-therapy-products-step-2b
31. 유럽의약품청 EMA 홈페이지
Available from: https://www.ema.europa.eu/en/ich-q9-quality-risk-management
32. 유럽의약품청 EMA 홈페이지
Available from: https://www.ema.europa.eu/en/events/ema-eatris-webinar-navigating- regulatory-requirements-advanced-therapy-medicinal-products-atmps
33. 유럽의약품청 EMA 홈페이지
Available from: https://www.ema.europa.eu/en/documents/chmp-annex/recommendations -eligibility-prime-scheme-adopted-chmp-meeting-13-16-december-2021_en.pdf
34. “ Committee for Advanced Therapies (CAT): work-plan-2021-Nov” EMA., Last modified Nov 3, Accessed Dec 16, 2021
Available from: https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-3-5 -november-2021-meeting_en.pdf
35. “Orphan designations-eu3212474” EMA. Last modified Nov 16, Accessed Jun. 24, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2474
36. “Orphan designations-eu3212478” EMA. Last modified Nov 16, Accessed Jun. 24, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2478
37. “Orphan designations-eu3212477” EMA. Last modified Nov 16, Accessed Jun. 24, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2477
38. “Orphan designations-eu3212473” EMA. Last modified Nov 16, Accessed Jun. 24, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2473
39. “Orphan designations-eu3212472” EMA. Last modified Nov 16, Accessed Dec 24, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2472
40. “Orphan designations-eu3182063” EMA. Last modified Nov 16, Accessed Dec 24, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2063
41. “Orphan designations-eu3171863” EMA. Last modified Dec 3, Accessed Dec 30, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1863
42. “Orphan designations-eu3141263” EMA. Last modified Dec 3, Accessed Dec 30, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1263
43. “Luxturna” EMA. Last modified Nov 11, Accessed Dec 24, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna
44. “Zynteglo” EMA. Last modified Dec 10, Accessed Dec 30, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo
45. PMDA 홈페이지
Available from: https://www.pmda.go.jp/int-activities/symposia/0106.html
46. 이한기 기자 “아스텔라스, 다이노와 차세대 유전자치료제 개발 제휴” 의약뉴스 (’21.12.03)
Available from: http://www.newsmp.com/news/articleView.html?idxno=219617
47. “인간 ES 세포의 새로운 세포주를 수립” (’21.12.08)
Available from: https://www.ncchd.go.jp/press/2021/211208.html
48. 眼科領域における国内第2号の再生医療等製品自家培養口腔粘膜上皮「オキュラルⓇ」 を発売(’21.12.10)
Available from: https://prtimes.jp/main/html/rd/p/000000031.000037877.html
49. 제6회 재생 의료 산학관 제휴 심포지엄 개최 (’21.12.14)
Available from: https://www.jsrm.jp/news/news-10952/
50. 일본재생의료학회 홈페이지
Available from: https://www.jsrm.jp/news/news-10943/